William Wierda

William Wierda is a CLL specialist and clinical trialist who has contributed to development and clinical evaluation of venetoclax, BTK inhibitors, and their combinations in CLL. He has led and co-led multiple phase I-III trials that established new treatment standards for both newly diagnosed and relapsed/refractory CLL. His work includes important studies of fixed-duration combination regimens offering potential for treatment-free remissions. He directs the CLL clinical program at MD Anderson and serves on CLL guideline panels and steering committees for major cooperative trials.